申请人:Lantheus Medical Imaging, Inc.
公开号:US20140030189A1
公开(公告)日:2014-01-30
Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.
本发明揭示了一种新型化合物,可用作核医学应用(PET成像)中的成像剂,用于成像心脏内神经。这些基于PET的放射性示踪剂可能表现出增加的稳定性,减少NE释放(从而减少副作用),改善定量数据和/或高亲和力,优于先前的放射性示踪剂。还提供了使用这些化合物成像心脏内神经的方法。在某些情况下,这些化合物是通过在多种位置上对某些化合物进行18F衍生化而开发的:芳基,烷基,酮基,苄基,β-烷氧基,γ-丙基烷氧基和β-丙基烷氧基。或者,还可以通过向胺基中添加甲基,和/或消除或掩盖邻二酚功能基的方式来使这些化合物更加稳定。